This dual mode of action of gemcitabine on replication fork progression, i.e., replisome stalling by inhibiting the RNR complex and causing dNTP shortage as well as causing DNA lesions by incorporating dFdC, can be quite effective in cancer therapy [18, 19]. The gene discussed is NR2E3; the disease is cancer.